In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib Program faculty:Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Resources:To download the slides associated with this podcast discussion, please visit the program page.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related